Off-the-shelf CAR T hits fast track

Posted 19 March 2025 PM

Imugene has had its shift from a clinical stage company to a commercial one sped up with a new designation from the FDA.

The FDA has granted Imugene's allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel), fast track designation for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the company announced today.

To see the whole article, please login

Popular

Aussie pharma Mum on having it all

Why young hot shots are quitting

Back on board after LinkedIn fiasco

MA treads carefully on PBS threat

Latest Jobs

Quality Control Scientist

Customer Service Team Leader

Principal Investigator

National Account Manager

Customer Care Associate Manager

See all...

Pharma in Focus Jobs

Marketing & Communications (2)

Sales & Customer Relations (31)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (2)

Other (18)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now